Paper Details

  1. Home
  2. Paper Details

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Author: BagnallA M, DuffyS, ForbesC, ShirranL, ter RietG

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ovarian cancer is a common and often deadly disease, with a 5-year survival rate of only 30% in the UK. While paclitaxel and platinum-based chemotherapy are standard treatments, many patients develop resistance and need alternative therapies. Topotecan is one option for second-line treatment, showing modest effectiveness, but more research is needed as current reviews are based on limited data.
Paper Details　
Original Abstract of the Article :
Ovarian cancer is the most common gynaecological cancer with an annual incidence of 21.6 per 100,000 in England and Wales. Due to the often asymptomatic nature of the early stages of the disease, most cases are not detected until the advanced stages. Consequently, the prognosis after diagnosis is po...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3310/hta5280

データ提供：米国国立医学図書館（NLM）

Topotecan for Ovarian Cancer: A Rapid and Systematic Review

Ovarian cancer, a silent and often aggressive disease, presents a formidable challenge to healthcare professionals. Imagine a vast desert where a hidden oasis lies buried beneath the sand, waiting to be discovered. Similarly, ovarian cancer often goes undetected in its early stages, making it difficult to diagnose and treat effectively. This review, conducted within the field of oncology, provides a rapid and systematic assessment of the clinical effectiveness and cost-effectiveness of topotecan, a drug used in the treatment of ovarian cancer. The review analyzes existing research, highlighting the potential benefits and limitations of topotecan, particularly for patients with advanced or resistant disease. The review also discusses the importance of exploring alternative second-line therapies for patients who have not responded to initial treatment.

Topotecan: A Potential Treatment for Ovarian Cancer

The review highlights the potential of topotecan as a second-line therapy for ovarian cancer. Although the evidence suggests modest efficacy, topotecan may offer a valuable treatment option for patients who have developed resistance to other therapies. However, the need for further research and clinical trials to better understand the long-term efficacy and safety of topotecan is emphasized.

Ovarian Cancer: Early Detection and Treatment

Early detection and prompt treatment are crucial for improving outcomes in ovarian cancer. While the review focuses on second-line therapies, it underscores the importance of raising awareness and promoting early screening to identify the disease in its early stages. If you experience any concerning symptoms such as abdominal bloating, pelvic pain, or changes in bowel habits, it is important to consult your doctor for proper evaluation and assessment.

Dr.Camel's Conclusion

Navigating the vast desert of ovarian cancer treatment requires a combination of research, clinical expertise, and patient advocacy. This review highlights the potential of topotecan as a second-line therapy, while emphasizing the need for continued research to improve treatment options for this challenging disease.

Date :
  1. Date Completed 2001-12-10
  2. Date Revised 2019-11-05
Further Info :

Pubmed ID

11701100

DOI: Digital Object Identifier

10.3310/hta5280

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.